Here’s an intriguing thought. What if we could reprogram cancer so it responds to treatment? That’s exactly what breast cancer experts are exploring.

Not all women respond to a common breast cancer drug called tamoxifen . Not to worry–these women can now be identified and switched to another medication before the disease turns deadly.

The U.S. Food and Drug Administration has approved a drug to be used for postmenopausal women with advanced hormone-receptor positive and HER2-negative breast cancer.

Obesity. Obesity. Obesity. It's spreading everywhere and touches most every chronic health condition. Now researchers find obesity could affect how well long-term breast cancer treatments work.

Postmenopausal breast cancer patients are often prescribed aromatase inhibitors after primary treatment to reduce the risks of disease recurrence. These drugs can cause bone density loss, though.

Breast cancer survivors who are taking certain medications are at higher risk for bone loss.  An available drug has been shown to overcome this serious side effect.

For years, tamoxifen  has been the gold standard for keeping breast cancer from reappearing. Updated research shows another medication known as an aromatase inhibitor is even more effective for post-menopausal women.

Most breast cancers are fueled by the female hormone estrogen. In an interesting twist, scientists have discovered that a male hormone ignites breast tumor growth in some women.

A drug currently being used to treat breast cancer has been shown to significantly reduce the risk of developing the disease. The aromatase inhibitor, Aromasin (exemestane), helps post-menopausal women avoid breast cancer altogether.

Women with large breast cancer tumors usually have two options - have chemotherapy to shrink the tumor before a lumpectomy - or have the entire breast removed. Now there are gentler options.